

# Radon and health effects other than lung cancer - PUMA, Wismut and other uranium miner studies


Michaela Kreuzer, Ph.D. (and on behalf of the PUMA study group)

Federal Office for Radiation Protection, Munich, Germany Head of Department "Radiation effects and risks from ionizing and nonionizing radiation" <u>mkreuzer@bfs.de</u>



# **Current risk evaluation**

"Radon causes no material risk for diseases other than lung cancer"



Absorbed doses from inhaled radon and its progeny to organs other than the respiratory tract are at least by a factor 100 lower [*Kendall and Smith 2002*]



# **Evidence from epidemiological studies**

- The association between radon and non-lung cancer has been mainly investigated in uranium miners
- Comparisons of mortality in miners with that of the general population (so-called SMR analyses) show increased risks for some diseases
   ⇒ often inconsistent across studies; unclear what is the cause
- Detailed analyses of exposure-response relationships are rare and indicate little evidence for material risk.
- Due to the low absorbed doses we expect if at all a small excess risk, thus large studies with a wide exposure range are necessary



# PUMA (Pooled uranium miner cohort study)

- Large number of deaths (~ 8,000 cancers other than lung cancer,
   ~ 17,500 circulatory and ~ 4,500 non-malignant respiratory diseases)
- Long average duration of follow-up, wide range of radon exposures
   ⇒ high statistical power to detect possibly small excess risks
- SMRs elevated for cancers of the lung, stomach, larynx, liver and gallbladder [*Richardson et al. 2020*],
- Analyses on the exposure-response relationship analyses not yet available



The Wismut cohort forms about 50% of PUMA, new findings based on follow-up by end of 2013 will be shown [*work in progress, unpublished*]



# Wismut cohort

Description	<ul> <li>n = 58,974 former employees of the Wismut company</li> <li>[Kreuzer et al. 2008; 2013; 2018; 2020]</li> </ul>
	<ul> <li>Mortality follow-up period: 1946-2013</li> </ul>
	<ul> <li>Individual data on exposure to radon and its progeny are available from a detailed job-exposure matrix</li> </ul>
Methods	Internal Poisson regression
	<ul> <li>Estimation of linear excess relative rate (ERR) per unit of cumulative exposure to radon in WLM (5-year lagged)</li> </ul>
	<ul> <li>Baseline stratification by age and calendar year</li> </ul>



#### Bundesamt

# Total group of cancers other than lung cancer

Published large studies	# of deaths	Person-years at risk	ERR/100 WLM 95% CI
Pooled 11 miner study Darby et al. 1995, BEIR VI 1999	1,179	669,694	<mark>0.01</mark> [-0.01; 0.02]
Wismut cohort* FU 2003, <i>Kreuzer et al. 2008</i>	3,340	1,762,208	<mark>0.014</mark> [0.006; 0.023]
Wismut cohort* FU 2013, <i>work in progress</i>	5,230	2,334,140	<mark>0.012</mark> [0.005; 0.020]

ERR/100 WLM: Excess relative risk per cumulative exposure to radon in Working Level Months (WLM) \* includes 4,000 millers which are excluded in PUMA



#### Bundesamt für Strahlenschutz **Total group of cancers other than lung cancer** *Wismut cohort with end of follow-up 2013* (*work in progress*)

WLM	Person-ys at risk	# deaths	Relative risk	95% CI	
0.	309 846	799	1.00		
>0-50	1 031 144	1 542	0.92	0.84-1.00	C)
50-99	145 406	326	0.94	0.82-1.06	<b>S6</b> <b>S7</b> <b>S7</b> <b>S7</b> <b>S7</b> <b>S7</b> <b>S7</b> <b>S7</b> <b>S7</b>
100-499	390 890	1 147	1.00	0.91-1.09	
500-999	259 623	789	1.02	0.91-1.12	L L L L L L L L L L L L L L L L L L L
1 000 -1 499	129 987	422	1.16	1.02-1.30	
1 500+	67 245	205	1.14	0.96-1.31	0,5
ERR/100 WLM	2 334 140	5 230	0.012	0.005; 0.019	Cumulative radon exposure [WLM]



# **Individual cancer sites**

#### Wismut cohort with end of follow-up 2013 (work in progress)

Cancer site	E	ERR / 100 W	(LM (95% CI)			Ν	ERR
Pharynx Liver						93 275	0.049 0.036
Colon, small intestine			•			482	0.026
Gallbladder		•				109	0.021
Non-Hodgkin lymphoma						135	0.020
Rectum						377	0.018
Tongue, mouth		•				72	0.017
Kidney						282	0.017
Multiple myeloma		•				96	0.016
Stomach		• •				795	0.016
Hodgkin lymphoma		•				41	0.016
Prostate						474	0.013
Bladder		•				276	0.006
Leukemia		+				203	0.004
Larynx						109	0.001
Pancreas		•				357	0.000
Esophagus		•				200	-0.018
Melanoma	•					70	-0.024
Brain, CNS						166	-0.029
	Γ	]					
	-0.05	0	0.05	0.1	0.15		



# Cancers of the respiratory tract excluding lung

Wismut cohort with end of follow-up 2013 (work in progress)

Cancer site	# deaths	ERR/100 WLM	95% CI	2,5 - All, n=286 ວົ
Tongue/mouth	72	0.017	-0.064; 0.099	<b>5</b> <b>5</b> <b>5</b> <b>5</b> <b>5</b> <b>5</b> <b>5</b> <b>5</b>
Pharynx	93	0.049	-0.041; 0.139	
Nose, nose cavity	12	0.020	-0.137; 0.178	1,0 Log
Larynx	109	0.001	-0.041; 0.043	
Total	286	0.016	-0.019; 0.051	0 500 1000 1500 200 Cumulative radon exposure [WLM]


- Absorbed doses from inhalation of radon progeny very high [Kendall and Smith 2002]
- ERR/WLM for total group is elevated, however, not statistically significant



## Liver cancer

### Wismut cohort with end of follow-up 2013 (work in progress)

- SMR: Consistently elevated in many uranium miner studies and PUMA
   [Tomasek 1993, Darby et al. 1995, Kreuzer et al. 2020, Kelly-Reif et al. 2019; Rage et al. 2019; Richardson et al. 2020]
- Wismut: n = 275 deaths
   ERR/100 WLM = 0.038; 95% CI: -0.002; 0.078
- Bias? Metastases of lung cancer in the liver may have been misclassified as primary liver cancer






## **Stomach cancer**

#### Wismut cohort with end of follow-up 2013 (work in progress)

- SMR: Consistently elevated SMRs in many uranium miner studies and PUMA
   [Tomasek 1993, Darby et al. 1995, Kreuzer et al. 2008; 2020, Schubauer-Berigan et al. 2009; Lane et al. 2018, Kelly-Reif et al. 2019; Rage et al. 2018, Richardson et al. 2020]
- Wismut: n = 795 deaths

ERR/WLM = 0.016; 95% CI: -0.001; 0.034 no linearity!





#### Bundesamt für Strahlenschutz Leukemia and its subtypes

## Wismut cohort with end of follow-up 2013 (work in progress)

- SMR: few studies show increased SMRs, e.g. Rericha et al. 2006; Kelly-Reif et al. 2019
- Wismut: n = 203 deaths, elevated excess for myeloic leukemia  $\Rightarrow$  chance?

	ICD 10	# deaths	ERR/WLM	95% CI
All	C91-C95 excl. C91.4	203	0.004	-0.029; 0.036
CLL	C91.1	70	-0.016	-0.057; 0.026
Non-CLL	C91-C95 excl. C91.1, C91.4	133	0.021	-0.027; 0.070
ML	C92	102	0.059	-0.015; 0.133

CLL: chronic lymphatic leukemia, ML: Myeloic leukemia



Bundesamt für Strahlenschutz

# **Circulatory diseases**

Major studies		All (100-199)	Cerebrovascular (l60-l69)	Ischemic heart diseases (120-125)
Eldorado cohort Lane et al. 2010	Deaths ERR/100 WLM 95% CI	n.a.	244 - <mark>0.04</mark> n.a.	1,235 <mark>-0.01</mark> n.a.
<b>French cohort</b>	Deaths	446	105	169
Rage <i>et al.</i> 2018	ERR/100 WLM	<mark>0.10</mark>	<mark>0.42</mark>	<mark>0.09</mark>
<i>Drubay et al.</i> 2015	95% CI	[-0.04; 0.29]	[0.04; 1.04]	[n.a.; 0.39]
Wismut cohort*	Deaths	9,039	2,073	4,613
FU 2008; Kreuzer	ERR/100 WLM	<mark>0.002</mark>	<mark>0.000</mark>	<mark>0.006</mark>
et al. 2013	95% CI	[-0.003; 0.006]	[-0.008; 0.009]	[-0.001; 0.012]
Wismut cohort*	Deaths	10,721	2,367	5,445
FU 2013, work in	ERR/100 WLM	<mark>0.002</mark>	<mark>-0.003</mark>	<mark>0.007</mark>
progress	95% CI	[-0.003; 0.006]	[-0.011; 0.005]	[0.001; 0.013]

\* includes 4,000 millers which are excluded in PUMA



# Non-malignant respiratory diseases

Major studies	ICD 10	All without silicosis (J00-J99 excl. J62,64,65)	COPD (J40-J44)
Wismut cohort*	Deaths	1,261	715
<i>Kreuzer et al.</i>	ERR/100 WLM	<mark>0.005</mark>	<mark>0.007</mark>
2013	95% CI	n.s.	n.s.
Wismut cohort*	Deaths	1,683	903
FU 2013, work in	ERR/100 WLM	<mark>0.001</mark>	- <mark>0.004</mark>
progress	95% CI	[-0.009; 0.012]	[-0.017; 0.010]

\* includes 4,000 millers which are excluded in PUMA COPD: Chronic obstructive pulmonary disease



# Summary – Wismut findings

### **Group of non-lung cancers**

- Significant exposure-response relationship
- Excess risk is low, particularly compared to lung cancer
  - (1.2% vs. 19% per 100 WLM)
- No material risk below 1,000 WLM

### Individual cancer sites

- Majority of ERR coefficients are positive (15 out of 19)
- Largest ERR coefficients estimated for pharynx, liver, ...

#### Other diseases than cancer

-Little evidence for excess risk



Bundesamt für Strahlenschutz

# Discussion

#### **Potential limitations**

- Confounding: No adjustment for e.g. alcohol, smoking, other risk factors
- Chance findings, particularly for individual cancer sites
- Bias due to uncertainty in exposure assessment, particularly in early years
- Validity of causes of deaths
- Lack of data on cancer incidence

#### **Comparison with other studies**

— Other studies: Few and inconsistent results  $\rightarrow$  wait for PUMA

#### Relevance, if an excess would be present

- Compensation claims of former and current workers
- Radon dose conversion factor, regulation at homes and at work